Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PAOX | Q6QHF9 | 1/20 | 0.36 |
| ▸ | MGLL | Q99685 | 2/20 | 0.34 |
| ▸ | PHGDH | O43175 | 1/20 | 0.34 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.33 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.33 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.33 |
| ▸ | LPAR3 | Q9UBY5 | 3/20 | 0.32 |
| ▸ | LPAR1 | Q92633 | 2/20 | 0.32 |
| ▸ | LPAR2 | Q9HBW0 | 2/20 | 0.32 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.32 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
| ▸ | GLA | P06280 | 1/20 | 0.32 |
| ▸ | TP53 | P04637 | 1/20 | 0.31 |
| ▸ | POLB | P06746 | 2/20 | 0.31 |
| ▸ | HTR1A | P08908 | 1/20 | 0.31 |
| ▸ | MC4R | P32245 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28843653 | 0.89 | MAPT (0.36) | LPAR3LPAR1LPAR2TDP1ALDH1A1 | |
| SCHEMBL16300835 | 0.82 | LPAR3 (0.39) | PAOXMGLLHDAC6HDAC2HDAC8 | |
| SCHEMBL6049095 | 0.80 | MAPT (0.48) | LPAR3LPAR1LPAR2ALDH1A1POLB | |
| SCHEMBL8007175 | 0.79 | TPI1 (0.32) | — | |
| SCHEMBL680884 | 0.79 | KDM4E (0.35) | TDP1ALDH1A1KDM4EPOLB | |
| SCHEMBL3431912 | 0.79 | MEN1 (0.35) | PAOXALDH1A1KDM4EPOLB | |
| SCHEMBL3431909 | 0.79 | S1PR1 (0.32) | PAOX | |
| SCHEMBL14268088 | 0.76 | POLB (0.39) | MGLLPHGDHALDH1A1POLB | |
| SCHEMBL18705243 | 0.75 | ANPEP (0.39) | POLB | |
| Pyrophosphoric Acid SCHEMBL31371950 | 0.72 | TDP1 (0.56) | PAOXMGLLPHGDHCYP1A2TDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 38 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9828378-B2 | Kinase inhibitors and methods of use | INTELLIKINE LLC (US) | 2017-11-28 | — | — | US | disclosed |
| US-9790228-B2 | Heterocyclic kinase inhibitors | INTELLIKINE LLC (US) | 2017-10-17 | — | — | US | disclosed |
| US-9724354-B2 | Combination of catalytic mTORC1/2 inhibitors and selective inhibitors of Aurora A kinase | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2017-08-08 | — | — | US | disclosed |
| US-20170209448-A1 | TREATMENT REGIMENS USING MULTIPLE PHARMACEUTICAL AGENTS | INTELLIKINE LLC | 2017-07-27 | — | — | US | disclosed |
| US-9669032-B2 | Enhanced treatment regimens using mTOR inhibitors | INTELLIKINE LLC (US) | 2017-06-06 | — | — | US | disclosed |
| US-9637492-B2 | Benzothiazole kinase inhibitors and methods of use | INTELLIKINE LLC (US) | 2017-05-02 | — | — | US | disclosed |
| US-20160287597-A1 | Treatment Regimens Using Multiple Pharmaceutical Agents | INTELLIKINE LLC | 2016-10-06 | — | — | US | disclosed |
| US-20160287595-A1 | Combination Pharmaceutical Compositions and Uses Thereof | CALITHERA BIOSCIENCES, INC. | 2016-10-06 | — | — | US | disclosed |
| US-20160287596-A1 | Benzoxazole Kinase Inhibitors and Methods of Use | FAETH THERAPEUTICS, INC. | 2016-10-06 | — | — | US | disclosed |
| US-20160271140-A1 | COMBINATION OF CATALYTIC MTORC 1/2 INHIBITORS AND SELECTIVE INHIBITORS OF AURORA A KINASE | MILLENNIUM PHARMACEUTICALS, INC. | 2016-09-22 | — | — | US | disclosed |
| US-20130209543-A1 | ENHANCED TREATMENT REGIMENS USING MTOR INHIBITORS | INTELLIKINE LLC (US) | 2013-08-15 | — | — | US | disclosed |
| US-8476282-B2 | Benzoxazole kinase inhibitors and methods of use | INTELLIKINE LLC (US) | 2013-07-02 | — | — | US | disclosed |
| US-8476431-B2 | Benzoxazole kinase inhibitors and methods of use | Itellikine LLC (US) | 2013-07-02 | — | — | US | disclosed |
| US-8450480-B2 | — | — | 2013-05-28 | — | — | US | disclosed |
| US-8450329-B2 | — | — | 2013-05-28 | — | — | US | disclosed |
| US-20110281866-A1 | HETEROCYCLIC KINASE INHIBITORS | INTELLIKINE, INC. (US) | 2011-11-17 | — | — | US | disclosed |
| US-20110124641-A1 | BENZOTHIAZOLE KINASE INHIBITORS AND METHODS OF USE | INTELLIKINE LLC | 2011-05-26 | — | — | US | disclosed |
| US-20110077268-A1 | KINASE INHIBITORS AND METHODS OF USE | INTELLIKINE LLC | 2011-03-31 | — | — | US | disclosed |
| US-20100190749-A1 | Benzoxazole kinase inhibitors and methods of use | FAETH THERAPEUTICS, INC. | 2010-07-29 | — | — | US | disclosed |
| US-20100184760-A1 | Benzoxazole kinase inhibitors and methods of use | FAETH THERAPEUTICS, INC. | 2010-07-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160287596-A1 | Benzoxazole Kinase Inhibitors and Methods of Use | BMX, MTOR, PDPK1 | PAOX 498/4885MGLL 1768/4885PHGDH 1884/4885 |
| US-20100184760-A1 | Benzoxazole kinase inhibitors and methods of use | BMX, MTOR, PDPK1 | PAOX 498/4885MGLL 1768/4885PHGDH 1884/4885 |
| US-20160287595-A1 | Combination Pharmaceutical Compositions and Uses Thereof | CDC25C, CCNC, CDC25B | PAOX 2380/4885MGLL 3987/4885PHGDH 768/4885 |
| US-20130209543-A1 | ENHANCED TREATMENT REGIMENS USING MTOR INHIBITORS | RICTOR, MTOR, RPTOR | PAOX 3514/4885MGLL 3390/4885PHGDH 1444/4885 |
| US-20110077268-A1 | KINASE INHIBITORS AND METHODS OF USE | MAP3K20, MAP3K1, PDPK1 | PAOX 1433/4885MGLL 1462/4885PHGDH 1202/4885 |
| US-20110124641-A1 | BENZOTHIAZOLE KINASE INHIBITORS AND METHODS OF USE | MTOR, PDPK1, PIKFYVE | PAOX 1241/4885MGLL 1487/4885PHGDH 1569/4885 |
| US-20160271140-A1 | COMBINATION OF CATALYTIC MTORC 1/2 INHIBITORS AND SELECTIVE INHIBITORS OF AURORA A KINASE | AURKC, AURKA, AURKB | PAOX 4563/4885MGLL 4365/4885PHGDH 3083/4885 |
| US-20100190749-A1 | Benzoxazole kinase inhibitors and methods of use | BMX, MTOR, PDPK1 | PAOX 498/4885MGLL 1768/4885PHGDH 1884/4885 |
| US-20170209448-A1 | TREATMENT REGIMENS USING MULTIPLE PHARMACEUTICAL AGENTS | MPL, MTX2, SLC10A1 | PAOX 1562/4885MGLL 2224/4885PHGDH 1885/4885 |
| US-20160287597-A1 | Treatment Regimens Using Multiple Pharmaceutical Agents | MPL, MTX2, SLC10A1 | PAOX 1562/4885MGLL 2224/4885PHGDH 1885/4885 |
| US-20110281866-A1 | HETEROCYCLIC KINASE INHIBITORS | MAP3K13, MAP3K3, CDK3 | PAOX 1631/4885MGLL 4287/4885PHGDH 907/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.